Sakar Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sakar Healthcare Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $16.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sakar Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $16.0M Trade | TransData Nexus

Sakar Healthcare Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $16.0M Total Trade · DGFT Verified

Sakar Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $16.0M across 6 products in 4 therapeutic categories. Based on 352 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cefixime ($4.5M), Ceftriaxone ($4.2M), Heparin ($4.0M).

Sakar Healthcare Limited — Export Portfolio & Destination Treemap

Sakar Healthcare Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sakar Healthcare Limited? — Company Overview & Market Position

Sakar Healthcare Limited, established on March 26, 2004, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company specializes in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical formulations, including liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections. Its product portfolio spans various therapeutic areas such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer.

The company is listed on the National Stock Exchange of India under the ticker symbol SAKAR. As of January 1, 2026, Sakar Healthcare Limited has a market capitalization of approximately ₹8.92 billion (INR), equivalent to about $99.2 million USD. In the fiscal year ending March 31, 2025, the company reported a revenue of ₹1.78 billion, marking a 15.53% increase from the previous year. The workforce comprises approximately 342 employees.

What Does Sakar Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cefixime$4.5M

Product Portfolio — Top 6 by Export Value

Sakar Healthcare Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cefixime	Advanced Antibiotics	$4.5M	91	2.6%	5
2	Ceftriaxone	Advanced Antibiotics	$4.2M	83	1.5%	7
3	Heparin	Cardiovascular	$4.0M	79	1.1%	6
4	Dexamethasone	Corticosteroids	$2.9M	57	1.6%	4
5	Flucloxacillin	Advanced Antibiotics	$447.2K	32	1.2%	11
6	Diazepam	CNS & Psychiatric	$87.9K	10	1.2%	14

Sakar Healthcare Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $16.0M. The top category is Advanced Antibiotics (57.0% of portfolio), followed by Cardiovascular (24.6%), indicating a concentrated portfolio with the top 5 products accounting for 99.5% of total export value.

Sakar Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sakar Healthcare Limited operates multiple state-of-the-art manufacturing facilities in Changodar, Ahmedabad, Gujarat. These facilities are equipped to produce a wide array of pharmaceutical products, including liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections. The company's liquid and lyophilized injection unit (small volume parenterals in ampoules and vials) has been approved by the European Union's Good Manufacturing Practice (EU GMP), ensuring adherence to stringent quality standards. Additionally, all manufacturing units are certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and have approvals from national drug authorities in countries such as Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Cambodia, Vietnam, Malawi, Namibia, Nigeria, Côte d'Ivoire, Philippines, and Peru.

3Key Leadership

Sakar Healthcare Limited is led by a team of experienced professionals committed to the company's growth and success. The key executives include:

Sanjay Surendra Shah: Chairman and Managing Director
Aarsh Sanjay Shah: Joint Managing Director
Rita Shah: Whole-Time Director
Sunil Vasantrao Marathe: Technical Director and Whole-Time Director
Dharmesh R. Thaker: Chief Financial Officer
Sudhir Ghuleas: Chief Operating Officer
Raviraj Kariaas: Senior Vice President of Finance and Accounts
Bharat Sukhlal Soni: Company Secretary and Compliance Officer
Nimesh Suthar: Senior Vice President of International Business

This leadership team is dedicated to steering Sakar Healthcare Limited towards continued success and expansion in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sakar Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sakar Healthcare Limited has made significant strides in establishing a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold EU GMP certification, which is a prerequisite for marketing pharmaceutical products in the European Union. This certification underscores the company's commitment to maintaining high-quality manufacturing standards.

In the United States, Sakar Healthcare Limited has been proactive in seeking regulatory approvals. The company has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for various products, aiming to enter the U.S. generic pharmaceutical market. While specific approval statuses are not detailed in the available sources, the company's efforts indicate a strategic focus on expanding its footprint in the U.S. market.

The company's adherence to international quality standards and its proactive approach to obtaining necessary certifications and approvals reflect its commitment to meeting the stringent requirements of these regulated markets.

2Emerging Markets

Sakar Healthcare Limited has strategically expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are exported to countries in these regions, including Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Cambodia, Vietnam, Malawi, Namibia, Nigeria, Côte d'Ivoire, Philippines, and Peru.

Sakar Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sakar Healthcare Limited has been active in seeking approvals from the U.S. Food and Drug Administration (FDA) to market its pharmaceutical products in the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, aiming to enter the U.S. generic pharmaceutical market. While specific approval statuses are not detailed in the available sources, the company's proactive approach indicates a strategic focus on expanding its footprint in the U.S. market.

The company's efforts to obtain FDA approvals reflect its commitment to adhering to international quality standards and regulatory requirements, positioning it to compete effectively in the U.S. pharmaceutical market.

2WHO & EU GMP

Sakar Healthcare Limited's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice (WHO-GMP) and the European Union's Good Manufacturing Practice (EU GMP). These certifications are indicative of the company's adherence to stringent international quality standards in pharmaceutical manufacturing.

The EU GMP certification, in particular, is crucial for marketing pharmaceutical products within the European Union, reflecting the company's commitment to maintaining high-quality manufacturing standards.

Sakar Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sakar Healthcare Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific competitors are not detailed in the available sources, the company's focus on obtaining international certifications, such as EU GMP and WHO prequalification, positions it to compete effectively in regulated markets.

2Key Differentiators

Sakar Healthcare Limited's key differentiators include its comprehensive product portfolio covering a wide range of therapeutic areas, its adherence to international quality standards evidenced by certifications like EU GMP and WHO-GMP, and its strategic focus on expanding into both regulated and emerging markets.

3Strategic Position

Sakar Healthcare Limited's current strategic direction emphasizes the expansion of its product offerings and market presence.

TransData Nexus Research · DGFT export records, industry analysis

Frequently Asked Questions — Sakar Healthcare Limited

How many pharmaceutical products does Sakar Healthcare Limited export from India?

Sakar Healthcare Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Cefixime ($4.5M), Ceftriaxone ($4.2M), Heparin ($4.0M), Dexamethasone ($2.9M), Flucloxacillin ($447.2K). Total export value is $16.0M.

What is Sakar Healthcare Limited's total pharmaceutical export value?

Sakar Healthcare Limited's total pharmaceutical export value is $16.0M, based on 352 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sakar Healthcare Limited cover?

Sakar Healthcare Limited exports across 4 therapeutic categories. The largest are Advanced Antibiotics (57.0%, 3 products), Cardiovascular (24.6%, 1 products), Corticosteroids (17.8%, 1 products).

Get Full Sakar Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.